Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8338352 | 0.82 | CYP2C9 (0.61) | ALDH1A1MEN1KMT2ACYP2C9CYP2C19 | |
| SCHEMBL27922741 | 0.82 | CHRM2 (0.62) | ALDH1A1MEN1KMT2AFFAR1CHRM2 | |
| SCHEMBL287925 | 0.82 | CA2 (0.54) | ALDH1A1 | |
| SCHEMBL156664 | 0.81 | MEN1 (0.56) | ALDH1A1MEN1KMT2AFFAR1GAA | |
| SCHEMBL8780612 | 0.81 | LMNA (0.55) | ALDH1A1FFAR1CYP2C19GAASMN1; SMN2 | |
| SCHEMBL31148844 | 0.81 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2ACYP2C9CYP2C19 | |
| SCHEMBL23105604 | 0.80 | LMNA (0.52) | ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1202552 | 0.80 | HTT (0.61) | ALDH1A1CYP2C9CYP2C19CHRM2FOLH1 | |
| SCHEMBL18487413 | 0.80 | FOLH1 (0.49) | ALDH1A1FOLH1 | |
| SCHEMBL841278 | 0.80 | L3MBTL1 (0.50) | MEN1KMT2ACYP2C19FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3328877-B1 | PEPTOID | THE UNIV OF DURHAM (GB) | 2022-08-24 | — | — | EP | claimed |
| US-20180201647-A1 | Peptoid | THE UNIVERSITY OF DURHAM (GB) | 2018-07-19 | — | — | US | claimed |
| US-20130165446-A1 | BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE | HORIKOSHI, HIROYOSHI (CA) | 2013-06-27 | — | — | US | claimed |
| EP-2581373-A1 | BENZO- OR PYRIDO-IMIDAZOLE DERIVATIVE | Fujita, Takashi (JP) | 2013-04-17 | — | — | EP | claimed |
| CN-118772034-A | Preparation process of 2-p-chlorophenyl-5- (trifluoromethyl) pyrrole-3-nitrile | 山东亿嘉农化有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-118772034-A | Preparation process of 2-p-chlorophenyl-5- (trifluoromethyl) pyrrole-3-nitrile | 山东亿嘉农化有限公司 | 2024-10-15 | — | — | CN | disclosed |
| US-20240327461-A1 | APELIN POLYPEPTIDES | AMGEN INC. (US) | 2024-10-03 | — | — | US | disclosed |
| US-11807693-B2 | Apelin polypeptides | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-4257152-A2 | APELIN POLYPEPTIDES | Amgen Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3674314-B1 | APELIN POLYPEPTIDES | AMGEN INC (US) | 2023-05-03 | — | — | EP | disclosed |
| CN-111269134-B | Preparation method of phenylglycine and derivatives thereof | 九江中星医药化工有限公司 | 2022-09-20 | — | — | CN | disclosed |
| EP-3328877-B1 | PEPTOID | THE UNIV OF DURHAM (GB) | 2022-08-24 | — | — | EP | disclosed |
| US-20130165446-A1 | BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE | HORIKOSHI, HIROYOSHI (CA) | 2013-06-27 | — | — | US | disclosed |
| EP-2581373-A1 | BENZO- OR PYRIDO-IMIDAZOLE DERIVATIVE | Fujita, Takashi (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-7271176-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-5527882-A | BRADYKININ | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-06-18 | — | — | US | disclosed |
| CN-1076690-A | SULFONAMIDOCARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 1993-09-29 | — | — | CN | disclosed |
| EP-0148752-B1 | PROTEASE INHIBITORS | G.D. Searle & Co. (US) | 1989-06-21 | — | — | EP | disclosed |
| US-4551279-A | Protease inhibitors | G. D. SEARLE & CO. (US) | 1985-11-05 | — | — | US | disclosed |
| EP-0148752-A2 | Protease inhibitors | G.D. Searle & Co. (US) | 1985-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201647-A1 | Peptoid | ARG1, ARGLU1, QPCT | ALDH1A1 4876/4885MEN1 988/4885KMT2A 1117/4885 |
| US-20130165446-A1 | BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE | PPARG, PPARA, PPARD | ALDH1A1 1612/4885MEN1 4822/4885KMT2A 1996/4885 |
| US-11807693-B2 | Apelin polypeptides | APLNR, FABP3, AP3B1 | ALDH1A1 3602/4885MEN1 1617/4885KMT2A 4510/4885 |
| US-20240327461-A1 | APELIN POLYPEPTIDES | APLNR, FABP3, AP3B1 | ALDH1A1 3602/4885MEN1 1617/4885KMT2A 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.